Vimarsana
Biggest News Aggregation in the World

Page 42 - Eceptor News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Eceptor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Eceptor Today - Breaking & Trending Today

Mediterranean diet intervention may not improve breast cancer prognosis in high-risk patients - Vimarsana News

Mediterranean diet intervention may not improve breast cancer prognosis in high-risk patients

Researchers discuss the results of a randomized controlled trial to explore the impact of diet on breast cancer recurrence.

Low serotonin levels observed in long COVID and other viral infections - Vimarsana News

Low serotonin levels observed in long COVID and other viral infections

Researchers identify a pathophysiological mechanism linking serotonin reduction to the multifaceted etiology of post-acute sequelae of COVID-19.

Canine transmission models provide insights into the neurological impacts of COVID-19 on human brains - Vimarsana News

Canine transmission models provide insights into the neurological impacts of COVID-19 on human brains

The histopathologic alteration caused by SARS‑CoV‑2 on mammalian neurological systems.

CAR T-cell therapy for multiple myeloma shows no difference in survival outcomes by race and ethnicity - Vimarsana News

CAR T-cell therapy for multiple myeloma shows no difference in survival outcomes by race and ethnicity

Patients with multiple myeloma treated with idecabtagene vicleucel, known as "ide-cel," a chimeric antigen receptor (CAR) T-cell therapy, had no difference in overall survival outcomes regardless of race and ethnicity, according to a study published in Blood Advances.

Oral diabetes and obesity meds danuglipron and orforglipron show promise but have gastrointestinal drawbacks - Vimarsana News

Oral diabetes and obesity meds danuglipron and orforglipron show promise but have gastrointestinal drawbacks

New orally-administered GLP-1 receptor agonists danuglipron and orforglipron show promise in treating type 2 diabetes and obesity, according to a systematic review. While effective in glycemic control and weight reduction, these drugs come with gastrointestinal side effects that may lead to treatment discontinuation.